Poongjeon Pharmacy풍전약품
298060 · KOSDAQ · ₩298060 · 풍전약품
₩2,370▲ ₩140 (6.28%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.6B | ₩825M | ₩696M | ₩396M | ₩439M |
| Cost of sales | ₩1.6B | ₩498M | ₩357M | ₩220M | ₩91M |
| Gross profit | ₩2B | ₩327M | ₩339M | ₩176M | ₩348M |
| Operating income | −₩4.7B | −₩11B | −₩13B | −₩13B | −₩12B |
| Net income | −₩1.7B | −₩12B | −₩24B | −₩23B | −₩23B |
| Net income to shareholders | −₩1.7B | −₩12B | −₩24B | −₩23B | −₩23B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩42B | ₩23B | ₩25B | ₩33B | ₩54B |
| Current assets | ₩13B | ₩2B | ₩13B | ₩10B | ₩20B |
| Cash and equivalents | ₩6.5B | ₩50M | ₩4.5B | ₩6.9B | ₩2.9B |
| Total liabilities | ₩8.3B | ₩9B | ₩4.9B | ₩8.5B | ₩9.4B |
| Current liabilities | ₩6B | ₩5.7B | ₩1.1B | ₩4.6B | ₩8.7B |
| Borrowings | ₩2.5B | ₩6.8B | ₩3.6B | ₩5.6B | ₩5.8B |
| Total equity | ₩34B | ₩14B | ₩20B | ₩25B | ₩45B |
| Shareholders' equity | ₩34B | ₩14B | ₩20B | ₩25B | ₩45B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.7B | −₩10B | −₩12B | −₩11B | −₩13B |
| Capital spending | ₩4.6B | ₩4.1B | ₩236M | ₩505M | ₩676M |
| Free cash flow | −₩9.2B | −₩14B | −₩12B | −₩12B | −₩14B |
Consolidated where available. Amounts in won.
Also known as: Poongjeon Pharmacy / 풍전약품 / 298060 / KRX:298060
Source: KRX statistical information